Press Releases
Press Releases
-
AntriaBio Formally Engages CRO for the Conduct of its Phase I First-in-Human Clinical Trial of AB101
-
AntriaBio Appoints Two Pharmaceutical Executives to its Board of Directors
-
AntriaBio Announces Offer to Amend Warrants to Purchase Shares of Common Stock
-
AntriaBio Announces Formation of Subsidiary and Plan to Raise Capital in South Korea
-
AntriaBio Announces $12 Million Private Placement
-
AntriaBio Announces Preclinical Proof of Concept for Once-Weekly Basal Insulin AB101 in Diabetic Miniature Swine
-
AntriaBio Announces Appointment of Michael Deperro as Vice President of Operations
-
AntriaBio Announces First Close of Private Placement Transaction
-
AntriaBio Receives Notice of Allowance on Patent Covering Microsphere Drug Delivery Platform
-
AntriaBio Announces New Product Candidate, AB301, a Weekly GLP-1 Agonist and Basal Insulin Combination, for Type 2 Diabetes